Although DNMTs were found to be differentially expressed in TGCTs [20], these nucleoside DNMT inhibitors were more limited in producing clinical benefit (although a recent trial using guadecitabine, the prodrug of DAC, in combination with cisplatin in metastatic platinum-refractory germ cell tumor patients produced promising results, with the combination being well tolerated and achieving a clinical benefit rate of 46% [41]). Here, DNMT1 is linked to germ cell tumor.